Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
31 stopped studies mapped to Large Cell Carcinoma and descendants · 81% state a reason
Over the 31 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT05453799 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer… | Phase 2 | suspended | Jul 12, 2022 | Northwestern University | Per sponsor letter, due to a business decision based on reprioritization of their internal… | Enrollment / accrual |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | Phase 1 / Phase 2 | terminated | Jan 29, 2008 | Daiichi Sankyo | Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated… | Safety / toxicity |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | Phase 2 | terminated | Jan 15, 2016 | Eisai Inc. | Overall response rate was 3% (only 1 out of 33 participants had confirmed PR). | Other (stated, no rule matched) |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | Phase 2 | withdrawn | Nov 13, 2014 | University of Texas Southwestern Medical Center | study was on hold for protocol redesign; decided to not move forward with study. | Other (stated, no rule matched) |
| NCT00568906 | Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung… | — | terminated | Dec 6, 2007 | Stanford University | not stated | Not stated |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients… | Phase 2 | terminated | Aug 10, 2009 | National Cancer Institute (NCI) | The study was closed to accrual due to the end of the clinical development program with cixutumumab. | Enrollment / accrual |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV… | Phase 2 | terminated | Mar 10, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With…(TAM-RT) | Phase 1 | withdrawn | Aug 6, 2015 | Gustave Roussy, Cancer Campus, Grand Paris | No patients enrolled | Enrollment / accrual |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients… | Phase 1 | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | Due to no accrual. | Enrollment / accrual |
| NCT01254734 | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck… | N/A | terminated | Dec 7, 2010 | City of Hope Medical Center | The study will be rewritten as a data registry study | Other (stated, no rule matched) |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid…(FACT) | Phase 2 / Phase 3 | terminated | Jul 26, 2007 | Mateon Therapeutics | Low rate of subject accrual | Enrollment / accrual |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid…(FACT2) | Phase 3 | withdrawn | Oct 5, 2012 | Mateon Therapeutics | Expected inability to recruit study participants in a reasonable amount of time. | Enrollment / accrual |
| NCT00369551 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating… | Phase 1 | terminated | Aug 29, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced… | Phase 3 | terminated | Jan 17, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | Phase 3 | terminated | May 7, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00042835 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials